Autoimmune Pulmonary Alveolar Proteinosis Completed Phase 2 Trials for Sargramostim (DB00020)

Back to Autoimmune Pulmonary Alveolar Proteinosis

Also known as: Pulmonary Alveolar Proteinosis, Autoimmune / Autoimmune pulmonary alveolar proteinosis (disorder) / Alveolar proteinosis / Pulmonary Alveolar Proteinosis / Pulmonary alveolar proteinosis (disorder)

IndicationStatusPhase
DBCOND0075037 (Autoimmune Pulmonary Alveolar Proteinosis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02835742
Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in JapanTreatment
NCT00901511
Inhaled GM-CSF Therapy of Autoimmune PAPTreatment